MoonLake Immunotherapeutics

Listed Company

MLTXCIK 0001821586NasdaqLarge AcceleratedPharmaceutical PreparationsE9FY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-227.32M

Total Assets

$424.43M

Equity

$304.48M

Shares Out

73.62M

Op. Cash Flow

$-196.01M

MLTX$19.70−63.66% · past yearDBEQ Basic

Daily closing prices

Business

MoonLake Immunotherapeutics is a clinical-stage biotechnology company developing SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody, to treat inflammatory skin and joint diseases. The company is advancing SLK through Phase 2 and Phase 3 clinical trials in hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and palmoplantar pustulosis. MoonLake operates as a single-asset company with contract manufacturing partnerships and no owned manufacturing facilities.

Summary from 10-K filed 2026-02-25

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	−203	−113	−32	−42	—
General and administrative	−42	−30	−22	−23	5
Total operating expenses	−245	−143	−54	−65	—
Operating loss	−245	−143	−54	−65	−5
Interest expense	−7	0	0	—	—
Other income, net	22	22	10	591,732	—
Loss before income tax	−230	−121	−44	−64	—
Income tax expense	−611,000	−282,000	−94,000	−36,366	—
Net loss	−230	−121	−44	−65	—
Of which: net loss attributable to controlling interests shareholders	−227	−119	−36	−50	−5
Of which: net loss attributable to noncontrolling interests shareholders	−3	−2	−8	−15	—
Net unrealized gain (loss) on marketable securities and short-term investments	−5	3	2	390,753	—
Actuarial gain (loss) on employee benefit plans	641,000	−87,000	−336,000	269,893	—
Other comprehensive income (loss)	−4	3	2	660,646	—
Comprehensive loss	−235	−119	−42	−64	—
Comprehensive loss attributable to controlling interests shareholders	−232	−116	−35	−49	—
Comprehensive loss attributable to noncontrolling interests	−3	−2	−8	−14	—
Weighted-average number of shares, basic (in shares)	64	63	49	29	—
Weighted-average number of shares, diluted (in shares)	64	63	49	29	—
Basic net loss per share attributable to controlling interest shareholders (USD per share)	−3.53	−1.89	−0.73	−1.7	—
Diluted net loss per share attributable to controlling interest shareholders (USD per share)	−3.53	−1.89	−0.73	−1.7	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	335	180	451	40	8
Short-term marketable debt securities	59	268	60	33	0
Other receivables	5	3	1	217,129	148,774
Prepaid expenses	23	23	2	4	1
Total current assets	422	474	514	77	10
Operating lease right-of-use assets	2	3	4	282,580	435,005
Property and equipment, net	577,000	722,000	320,865	49,389	45,739
Other non-current assets	596,000	0	—	—	—
Total non-current assets	3	4	12	331,969	45,739
Total assets	424	478	527	77	10
Trade and other payables	30	9	2	254,972	2
Accrued expenses and other current liabilities	15	12	7	7	5
Short-term portion of operating lease liabilities	1	1	1	153,629	0
Total current liabilities	45	22	10	8	21
Long-term debt	74	0	—	—	—
Long-term portion of operating lease liabilities	374,000	1	2	128,951	0
Pension liability	0	621,000	583,426	282,206	239,860
Total non-current liabilities	74	2	3	411,157	239,860
Total liabilities	120	25	13	8	21
Commitments and contingencies (Note 16)	—	—	—	—	—
Additional paid-in capital	767	677	610	129	42
Accumulated deficit	−463	−236	−117	−81	−54
Accumulated other comprehensive income	604,000	5	2	350,946	−168,177
Total shareholders equity	304	447	496	49	−12
Noncontrolling interests	0	7	18	20	0
Total equity	304	453	513	69	−12
Total liabilities and equity	424	478	527	77	10

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	3	1	400,000	200,000	—
Share-based compensation expense	13	7	7	10	—
Net periodic pension benefit (gain) loss for the qualified pension plan	−58,000	1,000	−85,000	304,031	—
Other non-cash items	−1	−227,000	128,000	68,454	—
Other receivables	−2	−2	−840,000	−68,355	—
Operating lease right-of-use assets	0	−6,000	−66,000	0	—
Prepaid expenses	561,000	−13	−6	−3	156,141
Other non-current assets	−587,000	0	0	—	—
Trade and other payables	21	7	2	−1	—
Operating lease liabilities	−1	−1	−222,000	−152,425	—
Accrued expenses and other current liabilities	3	5	−327,000	3	—
Net cash flow used in operating activities	−196	−117	−43	−56	−611,071
Purchase of short-term marketable debt securities	−265	−350	−176	−42	—
Proceeds from maturities of short-term marketable debt securities	468	145	151	10	—
Purchase of property and equipment	−35,000	−520,000	−284,000	−16,009	—
Net cash flow provided by (used in) investing activities	203	−206	−25	−32	—
Proceeds from long-term debt, net of issuance costs	73	0	0	—	—
Issuance of Class A Ordinary Shares, net of transaction costs	72	53	482	0	—
Stamp duty on capital injection from MoonLake to MoonLake AG	0	−1	−3	0	—
Net cash flow provided by financing activities	146	51	480	120	−58,063
Effect of movements in exchange rates on cash held	1	128,000	−76,000	8,540	—
Net change in cash and cash equivalents	154	−271	412	31	—
Cash paid for interest	5	0	0	—	—
Non-cash operating lease right-of-use assets obtained in exchange for lease obligations	0	555,000	4	435,005	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is MoonLake Immunotherapeutics's CIK number?

MoonLake Immunotherapeutics's SEC CIK number is 0001821586 (1821586). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find MoonLake Immunotherapeutics's SEC filings?

All of MoonLake Immunotherapeutics's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did MoonLake Immunotherapeutics last report earnings?

MoonLake Immunotherapeutics (MLTX) most recently filed an earnings 8-K with the SEC on May 11, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001821586-26-000005). This is MoonLake Immunotherapeutics's most recent earnings filing of record — not a forecast of its next earnings date.

What is MoonLake Immunotherapeutics's most recent earnings 8-K?

MoonLake Immunotherapeutics's latest earnings 8-K (Item 2.02) was filed May 11, 2026 under accession 0001821586-26-000005. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View MoonLake Immunotherapeutics's latest earnings 8-K →
Look up any company's CIK number →